Evaluation of Efficacy of Nevirapine Regimen versus Efavirenz Regimen

References

1. National AIDS Control Organization.Ministry of Health and Family Welfare, Government of India. 2009 August 26 [Last cited on 2010 Aug 31].
2. WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. World Health Organization: Geneva, 2010.
3. Nachega JB, Hislop M, Dowdy DW, Gallant JE, Chaisson RE, Regensberg L, et al. Efavirenz versus nevirapine- based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults. AIDS. 2008;22(16):2117-25.
4. Manosuthi W, Sungkanuparph S, Tantanathip P, Lueangniyomkul A, Mankatitham W, et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor- based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Clin Infect Dis. 2009;48(12):1752-59.
5. Van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.Lancet. 2004;363(9417):1253-1263.
6. De Beaudrap P, Etard JF, Gueye FN, Gueye M, Landman R, Girard PM, et al. Long termefficacy and tolerance of efavirenz and nevirapine-containing regimens in adult HIV type1 Senegalese patients. AIDS Res Hum Retroviruses. 2008;24(6):753-60.
7. Robert WS, Laua MS, Gregory KR, Victor DG, Sally WS, Richard TD, et al. AIDS Clinical Trials Group 384 Team Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003;349(24):2293–2303
8. Núñez M, Soriano V, Martín-Carbonero L, Barrios A, Barreiro P, Blanco F et al. SENC (Spanish efavirenz vs nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individuals. HIV Clin Trials. 2002;3(3):186–194.
9. Van den Berg-Wolf M, Hullsiek KH, Peng G, Kozal MJ, Novak RM, Chen L et al. CPCRA 058 Study Team, the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA), The International Network for Strategic Initiative in Global HIV Trials (INSIGHT). Virologic, immunologic, clinical, safety and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons. HIV Clin Trials. 2008;9(5):324–336.
10. Shubber Zaraa CA, Andrieux MI, Vitoria MA et al. Adverse events associated with nevirapine and efavirenz- based first-line antiretroviral therapy: a systematic review and meta-analysis. Nathanc AIDS 2013;27(9):1403–
11. Manosuthi W, Sungkanuparph S, Thakkinstian A, et al. Plasma nevirapine levels and 24 week efficacy in HIV- infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin. Clin Infect Dis 2006;43:253–55.
12. Cohen K, van Cutsem G, Boulle A, et al. Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV- associated tuberculosis. J Antimicrob Chemother 2008;61:389–9.
13. Cohen K, Grant A, Dandara C, et al. Effect of rifampicin- based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther 2009; 14: 687–95.
14. Gengiah TN, Holford NH, Botha JH, et al. The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis. Eur J Clin Pharmacol 2012;68:689–95.
15. Kate Shearer, Alana TB, Mhairi Maskew, Lawrence Long, Rebecca Berhanu, Ian Sanne, and Matthew P F. The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa. Journal of the International AIDS Society 2014,17:19065.
16. Sanjeev Sinha, Puroshottam Raghunandan, Rahul Chandrashekhar, Surendra K Sharma, Sanjiv Kumar et al. Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study .BMC Infectious Diseases 2013,13:482.
17. D'Arminio Monforte A, Lepri AC, Rezza G, Pezzoti P, Antinori A, Phillips AN, et al. Insights into the reasons for discontinuation of the first highly active antretroviral therapy (HAART) regimen in a cohort of antiretroviral naοve patients: Italian cohort of antiretroviral Naοve patients. AIDS 2000;14:499-507.
18. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: Risk factors Usha Adiga et al. Evaluation of Effectiveness of Nevirapine Regimen versus Efavirenz Regimen…. Indian Journal of Pharmacy and Pharmacology, April-June 2016;3(2);84-87 87 for virologic failure and adverse drug reactions. Ann Intern Med 1999;131:81-7.